Puma Biotechnology | PBYI - Assets


Puma Biotechnology reported $202.86M in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
Agios Pharmaceuticals USD 1.18B 112.24M Mar/2026
Alnylam Pharmaceuticals USD 5.13B 163.22M Mar/2026
Amgen USD 92.5B 1.92B Mar/2026
Biogen USD 29.48B 43.6M Mar/2026
BioMarin Pharmaceutical USD 8.59B 996.99M Mar/2026
Daiichi Sankyo JPY 3.82T 252.52B Dec/2025
Exelixis USD 2.59B 250.83M Mar/2026
Gilead Sciences USD 56.28B 2.74B Mar/2026
Glaxosmithkline GBP 62.87B 19.47B Mar/2026
Incyte USD 7.34B 381.14M Mar/2026
MacroGenics USD 217.87M 38.97M Mar/2026
Moderna USD 11.49B 850M Mar/2026
Novartis USD 118.53B 7.58B Mar/2026
Pfizer USD 207.62B 542M Mar/2026
PTC Therapeutics USD 2.87B 29.66M Mar/2026
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Regeneron Pharmaceuticals USD 40.87B 310.1M Mar/2026
Roche Holding CHF 98.2B 2.5B Jun/2026
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Sarepta Therapeutics USD 3.18B 170.77M Mar/2026
Takeda JPY 15.45T 44.34B Mar/2026
TG Therapeutics USD 1.53B 465.58M Mar/2026
Ultragenyx Pharmaceutical USD 1.3B 236M Mar/2026
Vanda Pharmaceuticals USD 488.95M 112.19M Dec/2025
Vertex Pharmaceuticals USD 26.48B 841.4M Mar/2026